Clinical trials: Arterial Inflammation
- Condition Arterial Inflammation
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Giant Cell Arteritis
KPL-301 for Subjects With Giant Cell Arteritis
The primary objective of the study is to evaluate the efficacy of mavrilimumab (KPL-301) versus placebo, co-administered with a 26-week corticosteroid taper, for maintaining sustained remission for 26 weeks in subjects with new…
- Trial name
- NCT03827018
- Testing
- mavrilimumab, prednisone
- Where
- 49 sites in United States, Australia and 13 more
- Volunteers
- 70 people
- Sponsor
- Kiniksa Pharmaceuticals, Ltd.
Acute Coronary Syndrome
Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event
The purpose of this study is to determine the effect of VIA-2291 as compared to placebo on vascular inflammation following 24 weeks of dosing.
- Trial name
- NCT00552188
- Testing
- VIA-2291
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Tallikut Pharmaceuticals, Inc.
Giant Cell Arteritis
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).
This study will evaluate the pharmacokinetics, pharmacodynamics, and safety of two dose levels of tocilizumab (TCZ) administered by intravenous (IV) infusion every 4 weeks (Q4W) to participants with giant cell arteritis (GCA).
- Trial name
- NCT03923738
- Testing
- Tocilizumab
- Where
- 2 sites in Switzerland
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Giant Cell Arteritis
Assessment of Giant Cell Arteritis Medical Practices in France
The purpose of this study is to describe medical practices in patients with GCA in terms of patient journey, diagnostic methods and specific GCA treatments since diagnosis.
- Trial name
- ARTEMIS (NCT03658889)
- Where
- France
- Volunteers
- 306 people
- Sponsor
- Chugai Pharma France
Subjects With Hyperlipidemia, Dyslipidemia
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
A study to assess the effects of proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibition on the arterial wall inflammation in patients with elevated lipoprotein(a).
- Trial name
- ANITSCHKOW (NCT02729025)
- Testing
- Evolocumab
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 129 people
- Sponsor
- Amgen
Giant Cell Arteritis
A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis
This study was designed to evaluate the efficacy and safety of secukinumab compared to placebo to maintain disease remission up to 28 weeks including corticosteroid tapering, as well as up to 1 year (52 weeks) in patients with…
- Trial name
- TitAIN (NCT03765788)
- Testing
- Secukinumab 300 mg, s.c., Prednisolone
- Where
- 11 sites in Germany
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Takayasu Arteritis
A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)
The purpose of this study is to evaluate the efficacy of ustekinumab compared to placebo, in combination with oral glucocorticoid (GC) taper regimen, in participants with relapsing Takayasu Arteritis (TAK).
- Trial name
- NCT04882072
- Testing
- Ustekinumab, Glucorticoid Taper Regimen
- Where
- 27 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Janssen Pharmaceutical K.K.
Psoriasis, Inflammation
A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors
The primary purpose of this proof-of-activity, phase 2 trial is to evaluate the safety and activity of orticumab in subjects with moderate to severe psoriasis and cardiometabolic risk factors.
- Conditions
- Psoriasis, Inflammation, Coronary Artery Disease, Cardiometabolic Syndrome
- Trial name
- NCT04776629
- Testing
- Orticumab
- Where
- 13 sites in United States
- Volunteers
- 77 people
- Sponsor
- Abcentra
Uveitis, Intermediate Uveitis
Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
This study is designed to determine the safety and tolerability of a single microinjection of triamcinolone acetonide (TRIESENCE®) into the suprachoroidal space (SCS) of patients who have non-infectious uveitis.
- Conditions
- Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
- Trial name
- NCT01789320
- Testing
- triamcinolone acetonide (Triesence®)
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Clearside Biomedical, Inc.
Coronary Artery Disease
Study Effect of VIA-2291 on Vascular Inflammation
This is a dose ranging study to compare the effect of VIA-2291 vs. Placebo on various inflammatory biomarkers in patients with recent acute coronary events
- Trial name
- NCT00358826
- Testing
- VIA-2291
- Where
- 12 sites in United States, Canada
- Volunteers
- 191 people
- Sponsor
- Tallikut Pharmaceuticals, Inc.
Coronary Heart Disease (CHD)
Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction
A Phase IIB Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction.
- Trial name
- GOLDILOX (NCT04610892)
- Testing
- MEDI6570
- Where
- 84 sites in United States, Australia and 9 more
- Volunteers
- 423 people
- Sponsor
- AstraZeneca
Giant Cell Arteritis
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
Sirukumab is a fully human anti-interleukin-6 (IL-6) immunoglobulin G1-kappa with a high affinity and specificity for binding to the human IL-6 molecule that may have therapeutic benefit in the treatment of giant cell arteritis…
- Trial name
- NCT02531633
- Testing
- Sirukumab, Prednisone
- Where
- 63 sites in United States, Australia and 11 more
- Volunteers
- 161 people
- Sponsor
- GlaxoSmithKline
Giant Cell Arteritis (GCA)
A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper…
- Trial name
- SELECT-GCA (NCT03725202)
- Testing
- Upadacitinib, Corticosteroid (CS)
- Where
- 172 sites in United States, Australia and 22 more
- Volunteers
- 429 people
- Sponsor
- AbbVie
Giant Cell Arteritis
An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of tocilizumab in participants with GCA.
- Trial name
- NCT01791153
- Testing
- Tocilizumab, Prednisone, Corticosteroids
- Where
- 78 sites in United States, Belgium and 12 more
- Volunteers
- 251 people
- Sponsor
- Hoffmann-La Roche
Atherosclerosis
Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy
This is a study to compare the effect of VIA-2291 vs. Placebo on various inflammatory biomarkers in patients with carotid stenosis scheduled for elective carotid endarterectomy
- Trial name
- NCT00352417
- Testing
- VIA-2291
- Where
- 3 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Tallikut Pharmaceuticals, Inc.
Giant Cell Arteritis
A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis
The primary purpose of this study is to evaluate the efficacy of guselkumab compared to placebo, in combination with a 26-week glucocorticoid (GC) taper regimen, in adult participants with new-onset or relapsing giant cell…
- Trial name
- THEIA (NCT04633447)
- Testing
- Guselkumab
- Where
- 30 sites in United States, Belgium and 7 more
- Volunteers
- 53 people
- Sponsor
- Janssen Research & Development, LLC
Giant Cell Arteritis
Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA
Primary Objective: To evaluate the efficacy of sarilumab in participants with giant cell arteritis (GCA) as assessed by the proportion of participants with sustained remission for sarilumab compared to placebo, in combination…
- Trial name
- NCT03600805
- Testing
- Sarilumab SAR153191, Prednisone
- Where
- 61 sites in United States, Argentina and 19 more
- Volunteers
- 83 people
- Sponsor
- Sanofi